HTLV-III DNA Cloning for Recombinant Polypeptide Expression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate for diagnosing, preventing, and treating AIDS caused by HTLV-III, as there is no effective method for early detection and treatment, and existing technologies fail to prevent the transmission of the virus through blood transfusions.

Innovation Solution

Cloning of HTLV-III DNA in recombinant/vector host systems to express immunoreactive polypeptides, enabling the development of methods for diagnosing AIDS, screening blood for the virus, and producing antibodies for immunotherapy and vaccination.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If HTLV-III DNA is cloned in recombinant/vector host systems to express immunoreactive polypeptides, then diagnostic accuracy and ability to detect HTLV-III in body fluids is improved, but device complexity and manufacturing complexity increase

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddevice complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The HTLV-III DNA genome is divided into specific segments or fragments that are cloned into recombinant vectors. These segmented DNA fragments are then inserted into host systems to express individual immunoreactive polypeptides, allowing for targeted detection and diagnosis while managing complexity through modular organization

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Recombinant vectors serve as intermediary carriers that facilitate the insertion and expression of HTLV-III DNA segments in host systems. These vectors act as mediators between the viral genome and the expression system, enabling controlled production of immunoreactive polypeptides for diagnostic applications

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If HTLV-III DNA is cloned to produce immunoreactive polypeptides for screening and diagnosis, then the ability to prevent virus transmission through blood transfusions is improved, but loss of time and productivity are worsened due to complex procedures

Engineering Contradiction:

Improveability to prevent virus transmissionVSAvoidloss of time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

HTLV-III DNA is cloned and immunoreactive polypeptides are produced in advance through recombinant host systems. These pre-produced polypeptides can be stored and used for rapid screening of blood donations, allowing preliminary identification of infected donors before transfusion occurs, thus preventing transmission while enabling efficient batch processing

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

Instead of working with the actual HTLV-III virus, the invention creates copies in the form of recombinant DNA sequences and expressed polypeptides. These copies serve as safe, manageable surrogates for diagnostic and screening purposes, eliminating the need to handle infectious material while maintaining diagnostic reliability

Inventive Principle:

Principle #26Copying

3Adaptability or versatility

If HTLV-III DNA is cloned and expressed to produce immunoreactive polypeptides, then the basis for immunotherapy and vaccination is improved, but manufacturing precision and ease of manufacture are worsened

Engineering Contradiction:

Improvebasis for immunotherapy and vaccinationVSAvoidease of manufacture

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The recombinant host systems are designed to be universal platforms that can express multiple different HTLV-III polypeptides by simply changing the inserted DNA sequence. This multi-functionality allows the same manufacturing infrastructure to produce various immunogenic components needed for different immunotherapy and vaccination strategies, increasing adaptability while maintaining manufacturing efficiency

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the detection of HTLV-III in body fluids, prevention of virus transmission, and provides a basis for immunotherapy and vaccination, improving diagnostic accuracy and reducing the risk of AIDS transmission through blood transfusions.

Implementation Method 1

Cloning of HTLV-III DNA in recombinant/vector host systems to express immunoreactive polypeptides

Methodology Applied

Scientific EffectTranscription:

Implementation Method 2

Cloning of HTLV-III DNA in recombinant/vector host systems to express immunoreactive polypeptides

Methodology Applied

Scientific EffectTranslation:

Data Source

PatentUS9328391B1Cloning and expression of HIV-1 DNA

Publication Date: 2016.05.03 NAT INST OF HEALTH AS REPRESENTED BY THE SEC OF HEALTH & HUMAN SERVICES

AI summary

The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.